A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 Gel

0.015%, three day treatment

DRUG

Vehicle gel

Vehicle gel, three day treatment

Trial Locations (21)

2217

Southderm Pty Ltd, Kogarah

St George Dematology and Skin Cancer Centre, Kogarah

23507

Virginia Clinical Research, Inc, Norfolk

27612

Wake Research Associates, Raleigh

30022

Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta

30263

Medaphase Inc, Newnan

33136

University of Miami, Skin Research Camp, Miami

37203

Dermatology Research Associates, Nashville

42301

Pedia Research LLC, Owensboro

46256

Dawes Fretein Clinical Research Group, LLC, Indianapolis

48059

Hamzavi Dermatology, Fort Gratiot

55432

Minnesota Clinical Study Center, Fridley

60089

Glazer Dermatology, Buffalo Grove

75703

Dermatology Associates of Tyler, Tyler

77598

Center for Clinical Studies, Webster

77845

J & S Studies, Inc., College Station

84124

Dermatology Research Center, Inc., Salt Lake City

90045

Dermatology Research Associates, Los Angeles

92056

Dermatology Specialists Inc, Oceanside

92117

Skin Surgery Medical Group Inc., San Diego

94114

Conant Medical Group, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00916006 - A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) | Biotech Hunter | Biotech Hunter